Castle Biosciences Stock Price, News & Analysis

Castle Biosciences (Nasdaq: CSTL) presented a poster at the CAP22 Annual Meeting showcasing its DiffDx-Melanoma test, which demonstrated over 98% accuracy in diagnosing melanocytic lesions. The test supports decisions for local excision in challenging cases where traditional methods are inconclusive. The company’s gene expression profile tests aim to aid dermatologists in providing confident treatment plans for approximately 300,000 ambiguous lesions annually in the U.S. Detailed case study results are available in the presented poster.

Castle Biosciences, Inc. (NASDAQ: CSTL) presented impactful data at the 2022 ASDS Annual Meeting, showcasing its DecisionDx®-SCC test for cutaneous squamous cell carcinoma (SCC). This 40-gene expression profile test helps predict metastasis risk, enabling better patient management. Notably, 42% of Mohs surgeons reported increased confidence in their treatment decisions when using the test. The study revealed that familiarity with DecisionDx-SCC was high among clinicians (97%), emphasizing its role in guiding risk-aligned management strategies.

Castle Biosciences (CSTL) announced a study validating its DecisionDx-Melanoma test published in the Journal of the American Academy of Dermatology. The test integrates tumor biology with clinicopathologic factors to provide personalized risk estimates for melanoma recurrence. Key findings include that 44% of patients could avoid sentinel lymph node biopsies without compromising survival rates exceeding 98%. The proprietary algorithm demonstrated a multivariate hazard ratio of 20.00 for predicting melanoma-specific survival, suggesting enhanced decision-making in cancer management.

Castle Biosciences (Nasdaq: CSTL) presented a framework for its diagnostic gene expression profile tests, MyPath Melanoma and DiffDx-Melanoma, aimed at enhancing clinical decision-making for melanoma diagnoses during the Maui Derm NP+PA Fall 2022 Conference. The proposed clinical workflow highlights how these tests can reduce diagnostic uncertainty, particularly in distinguishing between benign and malignant melanocytic lesions. The tests demonstrated a significant reduction in unnecessary excisions for benign results and increased visits for malignant cases, thus offering personalized treatment plans.

Castle Biosciences announced its three-year financial targets during an Investor Day event, projecting total revenue of $255-$330 million and positive net operating cash flow by December 31, 2025. The company emphasizes its foundational principles of exceptional employees and continuous improvement as essential for achieving these goals. Castle's leaders expressed confidence in their strong balance sheet and growth strategies, which include investments in innovative tests for dermatology, gastroenterology, and mental health.

Castle Biosciences (NASDAQ: CSTL) has been honored with the 2022 AZBio Fast Lane Award for its significant growth and commitment to patient care over the past 18 months. The company saw its workforce more than double, expanding from 201 to over 480 employees. Key achievements include strategic acquisitions in gastroenterology and mental health, the publication of 22 peer-reviewed papers, and a collaboration with the National Cancer Institute revealing a 27% improvement in survival rates for melanoma patients tested with DecisionDx-Melanoma.

Castle Biosciences (CSTL) will present at Baird’s 2022 Global Healthcare Conference on Sept. 13, 2022, at 2:00 p.m. ET. The presentation, led by CEO Derek Maetzold and CFO Frank Stokes, will be available via a live audio webcast on their website, with a replay for 90 days. Additionally, they will participate in one-on-one investor meetings at the Lake Street Best Ideas Growth Conference on Sept. 14, 2022. Castle is focused on diagnostics for conditions like skin cancers and Barrett’s esophagus.

Castle Biosciences, Inc. (CSTL) will host an Investor Day on Sept. 20, 2022, from 4:00 p.m. to 6:30 p.m. EDT, featuring insights on corporate strategy, growth plans, and financial outlook. Key executives, including Derek Maetzold and Frank Stokes, will lead the discussions. Attendees can register for the virtual event via the company's investor relations page. Castle focuses on innovative diagnostic tests for various health conditions, aiming to enhance patient care.

Castle Biosciences (CSTL) reported a 53% increase in Q2 2022 revenue to $34.8 million, alongside a 57% rise in total test reports delivered. The firm raised its full-year revenue guidance to $130–135 million. Key test volumes included 7,125 DecisionDx-Melanoma reports, up 39%, and 1,344 DecisionDx-SCC reports, up 71%. Despite positive revenue growth, net loss for Q2 was $(1.6) million, an improvement from $(8.8) million in 2021. Cash and equivalents stood at $273 million as of June 30, 2022.